research 52243 AH-001: An Emerging Androgen Receptor Degrader Showing Therapeutic Potential in Addressing Androgenetic Alopecia (AGA)
AH-001 could be a safer and more effective treatment for hair loss.
Search
for
Sort by
Research
90-120 / 1000+ results research The US FDA has approved the marketing of generic finasteride 5mg tablets by Actavis.
research Successful etanercept therapy in therapy refractory acrodermatitis continua suppurativa Hallopeau
Etanercept effectively treated a severe skin condition when other treatments failed.
research Selective Delivery of Tofacitinib Citrate to Hair Follicles Using Lipid-Coated Calcium Carbonate Nanocarrier Controls Chemotherapy-Induced Alopecia Areata
A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.
research Cardamonin-loaded liposomal formulation for improving percutaneous penetration and follicular delivery for androgenetic alopecia
A new liposomal formulation improves drug delivery and hair growth for treating hair loss without causing skin irritation.
research Pharmacophore Modeling and Three Dimensional Database Searching for Drug Design Using Catalyst: Recent Advances
The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.
![Synthesis, Biological Evaluation, and Molecular Docking of 4-Amino-2H-benzo[h]chromen-2-one Analogs Containing the Piperazine Moiety](/images/assets/2ecf4eed-7dbe-4f1a-83db-739625546cdd/small/31808.jpg)
research Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety
Analog 23 is a promising compound for prostate cancer treatment.
research Enhanced therapeutic effects of all-trans retinoic acid nanostructured lipid carrier composite gel drug delivery system for alopecia areata
The gel improves hair regrowth and reduces irritation in alopecia areata treatment.
research Health Canada has approved finasteride [Proscar; Merck Frosst] and doxazosin cotherapy
research Dissolving microneedles incorporating kopexil multicomponent crystals for improved transdermal delivery
Multicomponent crystals in microneedles improve drug delivery for hair loss treatment.
research A Full Factorial Design to Optimize Aminexil Nano Lipid Formulation to Improve Skin Permeation and Efficacy Against Alopecia
research Novel drugs of United States Food and Drug Administration approved in 2024
In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.
research Discovery of an Androgen Receptor Degrader Featuring a Pyridazinyl Glutarimide CRBN-Binding Motif for Transdermal Treatment of Androgenetic Alopecia
dAR-6–1 is a promising new treatment for hair loss that works better than minoxidil.
research Sometimes Marketing Efforts by Advocacy Organizations Can Lose Touch with the Nuances of Appropriateness
Advocacy groups should avoid marketing partnerships that may imply drug endorsements.
research Polymeric Based Bioinspired Microneedle Patch for the Treatment of Androgenetic Alopecia (AGA)
research Mechanistic synergy of hair growth promotion by the Avicennia marina extract and its active constituent (avicequinone C) in dermal papilla cells isolated from androgenic alopecia patients
Avicennia marina extract and avicequinone C can potentially promote hair growth and treat hair loss by interfering with hair loss mechanisms and boosting growth factors.
research Acitretin Loaded Nanocarrier Gel: Formulation and Exploration of In-vitro Release Kinetics
The new gel formulation for Acitretin improves topical delivery and reduces oral toxicity.
research Baricitinib for the Treatment of Alopecia Areata
Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
research PROTACs in 2025: from the laboratory concept to clinical breakthrough
PROTACs have become a breakthrough in medicine by effectively targeting and degrading specific proteins to treat diseases.
research Selective delivery of adapalene to the human hair follicle under finite dose conditions using polymeric micelle nanocarriers
Polymeric micelle nanocarriers deliver adapalene more effectively to hair follicles than commercial products.
research PCA: A tFNA-based targeted nucleic acid nanocomposite hydrogel for the treatment of androgenetic alopecia through the promotion of angiogenesis and hair follicle stem cell proliferation
PCA hydrogel promotes hair growth by enhancing blood vessel formation and hair follicle stem cell activity.
research America - A Diversity of Life Styles.
The drug showed promise in treating renal cell carcinoma with manageable side effects.
research Med Check
Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
research S3886 Concurrent Management of Crohn's Ileitis and Alopecia Universalis With Upadacitinib
Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
research Systematic review and quality analysis of studies on the efficacy of topical diphenylcyclopropenone treatment for alopecia areata
Topical DPCP is somewhat effective for hair loss in alopecia areata, but more research is needed.
research Mechanistic study of potential herbal extracts for development into hair growth-promoting product
Avicennia marina extract can significantly promote hair growth in androgenic alopecia patients.
research Response to Keith et al. Re: “Annurca Apple Nutraceutical Formulation Enhances Keratin Expression in a Human Model of Skin and Promotes Hair Growth and Tropism in a Randomized Clinical Trial”
research Malus pumila Mill. cv Annurca apple extract might be therapeutically useful against oxidative stress and patterned hair loss
Annurca apple extract may help treat hair loss and protect against oxidative stress.
research Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
A new topical treatment for hair loss is effective and safe with faster results.
research 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.